Hinova Pharmaceuticals Inc. announced that it has signed a Series B preferred shares purchase agreement of 2,188,244 preferred shares at a price of $2.28494 for the total gross proceeds of $5,000,006.24536 with Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623) on December 20, 2019. The company will issue 1.57% stakes to the investor.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.14 CNY | -2.44% | -3.96% | -47.88% |
Apr. 26 | Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 08 | China Stocks Fall Ahead of March Economic Data Release | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-47.88% | 370M | |
+34.01% | 51.07B | |
+35.62% | 38.61B | |
-8.02% | 38.78B | |
-8.98% | 27.32B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- 688302 Stock
- News Hinova Pharmaceuticals Inc.
- Hinova Pharmaceuticals Inc. announced that it expects to receive $5.000006 million in funding from Jilin Aodong Pharmaceutical Group Co., Ltd.